Page 8 - Laurus Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The pharmaceutical ingredients maker said that its wholly-owned subsidiary, Laurus Synthesis, incorporated a subsidiary by the name of Laurus Ingredients with effect from 9 January 2021.Laurus Ingredients, a step-down subsidiary of Laurus Labs, will undertake ingredients business and will also set up greenfield projects for new synthesis business. The announcement was made after market hours yesterday, 11 January 2021. Laurus Labs' consolidated net profit surged 328.4% to Rs 242.27 crore on a 59.9% increase in net sales to Rs 1,138.84 crore in Q2 September 2020 over Q2 September 2019. Shares ...

Shares of pharmaceutical companies were in focus on Monday with Nifty Pharma index hitting a fresh record high of 12,836 on the National Stock Exchange (NSE) in an otherwise subdued market. Cipla, Cadila Healthcare, Lupin, Sun Pharmaceutical Industries and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE. Meanwhile, Marksans Pharma, Suven Pharma, Novartis, Indoco Remedies, Glenmark Pharmaceuticals, Dr. Lal PathLabs, RPG Life Sciences, Strides Pharma Science and Laurus Labs from the S&P BSE Healthcare index were up between 2 per cent a...

Explore Now NEW DELHI: Six companies from the BSE500 pack have reported growth in profit margins for back-to-back four quarters. Five of these stocks have climbed up to 356 per cent so far this year, against a 12 per cent rise in the Sensex. They include Laurus Labs, Divi’s Laboratories, Mindtree, Aegis Logistics and Ambuja Cements. The sixth stock, Vakrangee, is up 6 per cent this year. The margin gains for these firms in the last four quarters were in the 5-13 percentage points range. Laurus Labs’ PAT margin stood at 21.27 per cent in September quarter compared with 17.73 per cent in Ju...